ICDs in women? A new meta-analysis sparks criticism Reply

A new meta-analysis finds that ICDs are not associated with a mortality benefit in women. The study, by Ghanbari and colleagues, appears in the Archives of Internal Medicine.

934 women and 3,810 men were randomized in the 5 trials included in the meta-analysis. For men, the trials, both individually and in the combined analysis, resulted in a statistically significant overall reduction in mortality.
Click to continue reading, including commentary from the blogging cardiologists Dr Wes and Dr Rich…

About these ads

Everybody in the (risk) pool! Survey finds frightening increase in CV risk 1

Fewer and fewer Americans are at low risk for cardiovascular disease, according to an important and frightening new report on long term trends from the National Health and Nutrition Examination Surveys (NHANES) of adults 25-74 years of age.

In the most recent survey (1999-2004) only about 8% of US adults had a low risk profile, despite favorable trends in reducing smoking and cutting cholesterol. The  overall increase in risk was due to the increased prevalence of diabetes, obesity, and hypertension, said the CDC’s Earl Ford, and his colleagues, in their report in Circulation.
Click to continue reading…

Editor insists prasugrel ghostwriter go public 1

You don’t need a medium or a seance to find a ghost. All it takes is a sharp-eyed editor.

According to a Reuters story by Brendan Borrell, the editor of the Journal of Managed Care Pharmacy,  Frederic Curtiss, insisted that a reluctant medical writer be listed as an author on a prasugrel article. The article, “Pharmacy Benefit Spending Poised to Increase for Antithrombotic Drug Therapy– Prasugrel Versus Clopidogrel,” appeared in the June  2009 issue of JMCP.

Curtiss insists that “all authors who contribute more than 1% to the manuscript” be disclosed, according to the Reuters report. Curtiss uses forensic methods, such as examining metadata in Word documents, to uncover hidden authors.
Click to continue reading…

ACC survey finds critical shortage of cardiologists now and in the future 1

Updated: A critical shortage of cardiologists exists today, and will only grow more severe in the future, according to a new report from the American College of Cardiology. The report finds a current shortage of more than 1,600 general cardiologists and nearly 2,000 interventional cardiologists. By 2025 the shortage of general cardiologists could grow to 16,000, and by 2050 the number of practicing cardiologists will need to double.

But not all experts agree that simply increasing the number of cardiologists is the best way to address the underlying problem, and several experts expressed skepticism about the finding that there is currently a shortage in interventional cardiologists.
Click to continue reading…

Phentermine and topiramate: a slimming combination 1

The combination of phentermine and topiramate resulted in substantial weight loss and good tolerability, according to a press release from Vivus Inc, the manufacturer of the combination drug called Qnexa.

Vivus announced today positive results from two pivotal phase 3 studies, EQUIP and CONQUER, in more than 3,750 patients. The company said the studies met their primary enpoints by demonstrating statistically significant weight loss with all three doses of Qnexa, as compared to placebo. Patients taking Qnexa also achieved significant improvements in cardiovascular and metabolic risk factors including blood pressure, lipid levels, and type 2 diabetes, the company reported.
Click to continue reading…

Lifetime exposure to lead linked to increased CV risk Reply

Lifetime cumulative exposure to lead is associated with significant increases in cardiovascular mortality, according to a new study in Circulation.

By measuring lead concentrations in the bone, the researchers, led by Marc Weisskopf, were able to asess long term exposure to lead. People with patella bone lead levels in the highest tertile were more than five times as likely to die of cardiovascular causes as people in the lowest tertile.
Click to continue reading…

“Dr Nobody” in JAMA editors flap speaks his mind 1

Jonathan Leo, the “Dr. Nobody” in the JAMA editors flap, has delivered a long and thoughtful response to the entire sorry episode in an article in the journal Society.

Among many issues, Leo discusses the academic freedom concerns raised by the case. (Recall that the JAMA editors initially demanded that Leo– along with any other JAMA letter writers– had no right to publish without permission from the editors.) Here is what Leo has to say:
Click to continue reading…

Are low-carb, high fat diets “fads”? 4

Should low-carb, high fat diets be considered “fad diets”? A Comment by Mann and Nye published in the Lancet simply assumes that these diets don’t have any scientific credibility, but we’ve seen a number of important studies in major publications, including recent trials in the NEJM by Shai et al and in JAMA, by Gardner et al, to suggest that these diets are very far from being dismissed as mere fads. In fact, there’s plenty of evidence to suggest that they should be taken very seriously indeed. (In fact, as any expert will reluctantly concede, there’s almost no good randomized, controlled data to conclusively demonstrate that any diet is better than any other.)
Click to continue reading…

FDA official reviews his own prasugrel review in NEJM 3

Now that prasugrel has finally been approved, EF Unger, one of its chief reviewers at the FDA, is providing insight into the FDA thought process in a perspective in the New England Journal of Medicine. Along the lines of the old TV ad for EF Hutton, when EF Unger speaks, people interested in prasugrel listen. As Unger writes, the “FDA grappled with a number of complex issues during the review process.” Discussing the TRITON-TIMI 38 trial, Unger says that:
Click to continue reading…

ESC: bivalirudin and otamixaban in ACS Reply

Two new ACS trials with the agents bivalirudin and otamixaban were presented today at the ESC and published simultaneously in the Lancet.

In the first trial, one year followup from the HORIZONS-AMI trial, Roxana Mehran and colleagues reported a reduction in the rate of net adverse clinical events and major bleeding in STEMI patients undergoing PCI who received bivalirudin compared to those who received heparin plus a glycoprotein IIb/IIIa inhibitor.
Click to continue reading…